Elevated PCSK9 levels are associated with a heightened risk of CVEs and mortality in SLE patients, suggesting the potential of PCSK9 as a promising target for developing future therapeutic strategies for SLE. The gene discussed is PCSK9; the disease is systemic lupus erythematosus.